CompletedNCT07590609

XingpiJieyu Formula + Escitalopram for depression

It tested xingpiJieyu Formula + Escitalopram for depression.

Depression, Liver-Stagnation and Spleen-DeficiencyDrugFrom 18 Years to 60 Years

The study in practice

Understand this study

Listed age limits: 18 years to 60 years.

Compensation and expense reimbursement have not been verified for this summary.

Study clarity

Study start dateStarted: May 23, 2023

Recruitment status: Completed
Enrollment listed in the registry: 150
Sponsor: Peking University Sixth Hospital
Sponsor type: University
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 4
Locations: China
Age range: From 18 Years to 60 Years
Official registry ID: NCT07590609
Official title: Research on the Therapeutic Effect and Clinical Indicators of XingpiJieyu Formula in the Treatment of Severe Liver Depression and Spleen Deficiency Type Depression Based on Abnormal Mitochondrial Energy Metabolism Pathway

Completed

Beijing

FAQ

Who is behind this study?

The study sponsor is Peking University Sixth Hospital, a university.

Did this study involve medication?

Yes. The study involved medication, including XingpiJieyu Formula (XPJYF) + Escitalopram and XingpiJieyu Placebo + Escitalopram.

Who was this study for?

Listed age limits: 18 years to 60 years.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.